Supplementary Table S2 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Wenhua Sang,Yiduo Zhou,Haiyan Chen,Chengxuan Yu,Lisi Dai,Zhongkun Liu,Lang Chen,Yimin Fang,Panpan Ma,Xiangji Wu,Hao Kong,Wenting Liao,Hong Jiang,Junbin Qian,Da Wang,Yun-Hua Liu

DOI: https://doi.org/10.1158/2159-8290.25191539

2024-01-01

Abstract:Supplementary Table S2. Detailed information of human pancreatic tissue array.

What problem does this paper attempt to address?

Supplementary Table S4 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Wenhua Sang,Yiduo Zhou,Haiyan Chen,Chengxuan Yu,Lisi Dai,Zhongkun Liu,Lang Chen,Yimin Fang,Panpan Ma,Xiangji Wu,Hao Kong,Wenting Liao,Hong Jiang,Junbin Qian,Da Wang,Yun-Hua Liu

DOI: https://doi.org/10.1158/2159-8290.25183960

2024-01-01

Abstract:Supplementary Table S4. Primers used for qPCR or generating knockout/knockdown constructs.
Supplementary Table S1 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Wenhua Sang,Yiduo Zhou,Haiyan Chen,Chengxuan Yu,Lisi Dai,Zhongkun Liu,Lang Chen,Yimin Fang,Panpan Ma,Xiangji Wu,Hao Kong,Wenting Liao,Hong Jiang,Junbin Qian,Da Wang,Yun-Hua Liu

DOI: https://doi.org/10.1158/2159-8290.25191542

2024-01-01

Abstract:Supplementary Table S1. MAGeCK analysis of CRISPR screen results to identify regulator of immune evasion in orthotopic PDAC mouse models.
SUPPLEMENTARY DATA FIGURES from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Wenhua Sang,Yiduo Zhou,Haiyan Chen,Chengxuan Yu,Lisi Dai,Zhaobo Liu,Lang Chen,Yimin Fang,Pingping Ma,Xiaochong Wu,Hao Kong,Wenting Liao,Jingping Hong,Junbin Qian,Da Wang,Yun-Hua Liu

DOI: https://doi.org/10.1158/2159-8290.25183972

2024-01-01

Abstract:Supplementary Figure S1. In vivo CRISPR screens to identify critical drivers of immune evasion; Supplementary Figure S2. Effects of Ripk2 depletion on tumor growth; Supplementary Figure S3. RIPK2 is overexpressed in human and mouse PDAC tissues; Supplementary Figure S4. Ablation of RIPK2 disrupts the desmoplastic TME; Supplementary Figure S5. RIPK2 modulates the immune profile and impairs anti-tumor T cell response; Supplementary Figure S6. RIPK2 restricts the activation and effector states of CD8+ T cells by impairing antigen presentation; Supplementary Figure S7. RIPK2 promotes MHC-I trafficking to lysosomes via NBR1; Supplementary Figure S8. RIPK2 ubiquitination promotes NBR1-mediated MHC-I degradation; Supplementary Figure S9. RIPK2 ablation potentiates the efficacy of PD-1 blockade; Supplementary Figure S10. Diagram illustrating RIPK2-mediated degradation of MHC I through autophagy–lysosome system.
Data from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Wenhua Sang,Yiduo Zhou,Haiyan Chen,Chengxuan Yu,Lisi Dai,Zhongkun Liu,Lang Chen,Yimin Fang,Panpan Ma,Xiangji Wu,Hao Kong,Wenting Liao,Hong Jiang,Junbin Qian,Da Wang,Yun-Hua Liu

DOI: https://doi.org/10.1158/2159-8290.cd-23-0584

IF: 28.2

2024-01-01

Cancer Discovery

Abstract:AbstractPancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancy because of its aggressive nature and the paucity of effective treatment options. Almost all registered drugs have proven ineffective in addressing the needs of patients with PDAC. This is the result of a poor understanding of the unique tumor–immune microenvironment (TME) in PDAC. To identify druggable regulators of immunosuppressive TME, we performed a kinome- and membranome-focused CRISPR screening using orthotopic PDAC models. Our data showed that receptor-interacting protein kinase 2 (RIPK2) is a crucial driver of immune evasion of cytotoxic T-cell killing and that genetic or pharmacologic targeting of RIPK2 sensitizes PDAC to anti–programmed cell death protein 1 (anti–PD-1) immunotherapy, leading to prolonged survival or complete regression. Mechanistic studies revealed that tumor-intrinsic RIPK2 ablation disrupts desmoplastic TME and restores MHC class I (MHC-I) surface levels through eliminating NBR1-mediated autophagy-lysosomal degradation. Our results provide a rationale for a novel combination therapy consisting of RIPK2 inhibition and anti–PD-1 immunotherapy for PDAC.Significance:PDAC is resistant to almost all available therapies, including immune checkpoint blockade. Through in vivo CRISPR screen, we identified that RIPK2 plays a crucial role in facilitating immune evasion by impeding antigen presentation and cytotoxic T-cell killing. Targeting tumor-intrinsic RIPK2 either genetically or pharmacologically improves PDAC to anti–PD-1 immunotherapy.See related commentary by Liu et al., p. 208.This article is featured in Selected Articles from This Issue, p. 201
Supplementary Tables from LIMS1 Promotes Pancreatic Cancer Cell Survival under Oxygen–Glucose Deprivation Conditions by Enhancing HIF1A Protein Translation

Chongbiao Huang,Yang Li,Zengxun Li,Yang Xu,Na Li,Yi Ge,Jie Dong,Antao Chang,Tiansuo Zhao,Xiuchao Wang,Hongwei Wang,Shengyu Yang,Keping Xie,Jihui Hao,He Ren

DOI: https://doi.org/10.1158/1078-0432.22470555

2023-01-01

Abstract:7 Supplementary Tables: Supplementary Table S1. Association between LIMS1 expression and clinicopathological features of patients with PDAC. Supplementary Table S2. Association between LIMS1 mRNA expression and clinicopathological features of PDAC patients from TCGA. Supplementary Table S3. Cox's proportional hazards model analysis of prognostic factors in patients with pancreatic ductal adenocarcinoma (PDAC) Supplementary Table S4. Association between LIMS1 expression and clinicopathological features of patients with esophageal cancer. Supplementary Table S5. Association between LIMS1 expression and clinicopathological features of patients with lung adenocarcinoma. Supplementary Table S6. Main antibodies and reagents. Supplementary Table S7. Primers and oligonucleotides sequences.
Receptor-interacting protein kinase 2 is an immunotherapy target in pancreatic cancer

Wenhua Sang,Yiduo Zhou,Haiyan Chen,Chengxuan Yu,Lisi Dai,Zhongkun Liu,Lang Chen,Yimin Fang,Panpan Ma,Xiangji Wu,Hao Kong,Wenting Liao,Hong Jiang,Junbin Qian,Da Wang,Yun-Hua Liu,Chengxuan YU

DOI: https://doi.org/10.1158/2159-8290.cd-23-0584

IF: 28.2

2023-10-14

Cancer Discovery

Abstract:Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancies due to its aggressive nature and the paucity of effective treatment options. Almost all registered drugs have proven ineffective in addressing the needs of PDAC patients. This is the result of a poor understanding of the unique tumor immune microenvironment (TME) in PDAC. To identify druggable regulators of immunosuppressive TME, we performed a kinome- and membranome-focused CRISPR screening using orthotopic PDAC models. Our data showed that RIPK2 is a crucial driver of immune evasion of cytotoxic T-cell killing and that genetic or pharmacological targeting of RIPK2 sensitizes PDAC to anti-PD-1 immunotherapy, leading to prolonged survival or complete regression. Mechanistic studies revealed that tumor-intrinsic RIPK2 ablation disrupts desmoplastic TME and restores MHC-I surface levels through eliminating NBR1-mediated autophagy-lysosomal degradation. Our results provide a rationale for a novel combination therapy consisting of RIPK2 inhibition and anti-PD-1 immunotherapy for PDAC.

oncology
Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren A. Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John S. Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen K. Tumula,Vikas Bhardwaj,James Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/2159-8290.22528410.v1

2023-01-01

Abstract:PDF file, 95K, Antibodies used in reverse-phase protein microarrays
Supplementary Table 2 from HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma

Hong Zheng,Weipeng Zhao,Cihui Yan,Crystina C. Watson,Michael Massengill,Mengyu Xie,Chris Massengill,David R. Noyes,Gary V. Martinez,Roha Afzal,Zhihua Chen,Xiubao Ren,Scott J. Antonia,Eric B. Haura,Brian Ruffell,Amer A. Beg

DOI: https://doi.org/10.1158/1078-0432.22454714

2023-01-01

Abstract:Supplementary Table 2. Probe sets showing 2-fold difference in expression in 2 independent experiments with romidepsin treatment of LKR. Probe sets with very low expression (cutoff of <100 under all tested conditions) were removed. Probe set ID, direction of change after romidepsin treatment, accession number and gene symbol when available are indicated.
Supplementary Table S2 from an Inflammatory Checkpoint Generated by IL1RN Splicing Offers Therapeutic Opportunity for KRAS-Mutant Intrahepatic Cholangiocarcinoma

Mao Zhang,Yingying Huang,Jiaomeng Pan,Chen Sang,Youpei Lin,Liangqing Dong,Xia Shen,Yingcheng Wu,Guohe Song,Shuyi Ji,Fen Liu,Mengcheng Wang,Yuyan Zheng,Sirui Zhang,Zefeng Wang,Jianke Ren,Daming Gao,Jian Zhou,Jia Fan,Wu Wei,Jian Lin,Qiang Gao

DOI: https://doi.org/10.1158/2159-8290.24249146.v1

2023-01-01

Abstract:Supplementary Table S2. Differential ASEs, primers and sequences information.
Supplementary Table S1 from an Inflammatory Checkpoint Generated by <i>il1rn</i> Splicing Offers Therapeutic Opportunity for &Lt;i>kras</i>-Mutant Intrahepatic Cholangiocarcinoma

Mao Zhang,Yingying Huang,Jiaomeng Pan,Chen Sang,Youpei Lin,Liangqing Dong,Xia Shen,Yingcheng Wu,Guohe Song,Shuyi Ji,Fen Liu,Mengcheng Wang,Yuyan Zheng,Sirui Zhang,Zefeng Wang,Juanjuan Ren,Daming Gao,Jian Zhou,Jia Fan,Wei Wu,Jian Lin,Qiang Gao

DOI: https://doi.org/10.1158/2159-8290.24249149

2023-01-01

Abstract:Supplementary Table S1. Samples and transcriptomics information.
Supplementary Table S3 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy

Jiang Chen,Zohreh Amoozgar,Xin Liu,Shuichi Aoki,Zelong Liu,Sarah M. Shin,Aya Matsui,Alexei Hernandez,Zhangya Pu,Stefan Halvorsen,Pin-Ji Lei,Meenal Datta,Lingling Zhu,Zhiping Ruan,Lei Shi,Daniel Staiculescu,Koetsu Inoue,Lance L. Munn,Dai Fukumura,Peigen Huang,Slim Sassi,Nabeel Bardeesy,Won Jin Ho,Rakesh K. Jain,Dan G. Duda

DOI: https://doi.org/10.1158/2326-6066.25523060.v1

2024-01-01

Abstract:Supplementary Table S3: IMC panel.
Supplementary Table 2 from MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

Mengyu Xie,Hong Zheng,Ranjna Madan-Lala,Wenjie Dai,Nicholas T. Gimbrone,Zhihua Chen,Fumi Kinose,Sarah A. Blackstone,Keiran S.M. Smalley,W. Douglas Cress,Eric B. Haura,Uwe Rix,Amer A. Beg

DOI: https://doi.org/10.1158/0008-5472.22422747

2023-01-01

Abstract:Drug screening data used in Figure 2 are shown, including drug names, cell viability and expression levels of chemokines.
Supplementary Table S5 from an Inflammatory Checkpoint Generated by IL1RN Splicing Offers Therapeutic Opportunity for KRAS-Mutant Intrahepatic Cholangiocarcinoma

Mao Zhang,Yingying Huang,Jiaomeng Pan,Chen Sang,Youpei Lin,Liangqing Dong,Xia Shen,Yingcheng Wu,Guohe Song,Shuyi Ji,Fen Liu,Mengcheng Wang,Yuyan Zheng,Sirui Zhang,Zefeng Wang,Jianke Ren,Daming Gao,Jian Zhou,Jia Fan,Wu Wei,Jian Lin,Qiang Gao

DOI: https://doi.org/10.1158/2159-8290.24249137

2023-01-01

Abstract:Supplementary Table S5. Top 200 genes for each T cell cluster obtained by wilcox test with the rank_genes_groups function in Scanpy.
Supplementary Tables from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy

Jialei Weng,Zheng Wang,Zhiqiu Hu,Wenxin Xu,Jia-Lei Sun,Fu Wang,Qiang Zhou,Shaoqing Liu,Min Xu,Minghao Xu,Dongmei Gao,Ying-Hao Shen,Yong Yi,Yi Shi,Qiongzhu Dong,Chenhao Zhou,Ning Ren

DOI: https://doi.org/10.1158/0008-5472.25964573.v1

2024-01-01

Abstract:The Supplementary Data consist of: Supplementary Tables S1-7
Additional File 29 of Proteogenomic Insights into the Biology and Treatment of Pancreatic Ductal Adenocarcinoma

Yexin Tong,Mingjun Sun,Lingli Chen,Yunzhi Wang,Jinwen Feng,Lingling Li,Xuan Zhang,Yumeng Cai,Jingbo Qie,Yanrui Pang,Ziyan Xu,Jingxia Zhao,Xiaolei Zhang,Yang Liu,Sha Tian,Zhaoyu Qin,Fan Zhang,Jiajun Zhu,Yifan Xu,Wenhui Lou,Yuan Ji,Jian Zhao,Fuchu He,Yingyong Hou,Ding Chen

DOI: https://doi.org/10.6084/m9.figshare.21628900

2022-01-01

Abstract:Additional file 29: Table S7. Characterization of Immune Infiltration in PDAC. Table S7A Matrix of xCell signatures significantly altered in 5 immune subgroups. Table S7B Matrix describing the expression of proteins in 5 immune subgroups. Table S7C Matrix of GSVA scores of pathways significantly altered in 5 immune subgroups, transcriptome level. Table S7D Matrix of amplification/deletion events of genes in 5 immune subgroups. Table S7E Matrix describing the expression of proteins involved in TCA cycle.
Supplementary Table S3 from Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non–Small Cell Lung Cancer

Haniel A. Araujo,Ximo Pechuan-Jorge,Teng Zhou,Minh Truong Do,Xin Hu,Frank R. Rojas Alvarez,Maria E. Salvatierra,Heladio P. Ibarguen,Richard Lee,Rashi Raghulan,Harshit Shah,Mariela A. Moreno Ayala,Kevin Chen,Nataliya Tovbis Shifrin,Shuhong Wu,Luisa M. Solis Soto,Marcelo V. Negrao,Don L. Gibbons,David S. Hong,Jack A. Roth,John V. Heymach,Jianjun Zhang,Jingjing Jiang,Mallika Singh,Jacqueline A.M. Smith,Elsa Quintana,Ferdinandos Skoulidis

DOI: https://doi.org/10.1158/2159-8290.27435619

2024-01-01

Abstract:Supplementary table S3. List of antibodies used for immunohistochemical studies.
Supplementary Table 2 from Activation of the PI3K/AKT Pathway Induces Urothelial Carcinoma of the Renal Pelvis: Identification in Human Tumors and Confirmation in Animal Models

Chao-Nan Qian,Kyle A. Furge,Jared Knol,Dan Huang,Jindong Chen,Karl J. Dykema,Eric J. Kort,Aaron Massie,Sok Kean Khoo,Kristin Vanden Beldt,James H. Resau,John Anema,Richard J. Kahnoski,Hans Morreau,Philippe Camparo,Eva Comperat,Mathilde Sibony,Yves Denoux,Vincent Molinie,Annick Vieillefond,Charis Eng,Bart O. Williams,Bin Tean Teh

DOI: https://doi.org/10.1158/0008-5472.22382943.v1

2023-01-01

Abstract:Supplementary Table 2 from Activation of the PI3K/AKT Pathway Induces Urothelial Carcinoma of the Renal Pelvis: Identification in Human Tumors and Confirmation in Animal Models
Supplementary Table I and II from PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer

Nisha Nagarsheth,Dongjun Peng,Ilona Kryczek,Ke Wu,Wei Li,Ende Zhao,Lili Zhao,Shuang Wei,Timothy Frankel,Linda Vatan,Wojciech Szeliga,Yali Dou,Scott Owens,Victor Marquez,Kaixiong Tao,Emina Huang,Guobin Wang,Weiping Zou

DOI: https://doi.org/10.1158/0008-5472.22409408.v1

2023-01-01

Abstract:This is Supplementary Tables I and II Table 1: RT-PCR primers and ChIP primers Table 2: shRNA Sequences
Supplementary Table S2 from Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Zhong-Yi Dong,Wen-Zhao Zhong,Xu-Chao Zhang,Jian Su,Zhi Xie,Si-Yang Liu,Hai-Yan Tu,Hua-Jun Chen,Yue-Li Sun,Qing Zhou,Jin-Ji Yang,Xue-Ning Yang,Jia-Xin Lin,Hong-Hong Yan,Hao-Ran Zhai,Li-Xu Yan,Ri-Qiang Liao,Si-Pei Wu,Yi-Long Wu

DOI: https://doi.org/10.1158/1078-0432.22462071

2023-01-01

Abstract:Clinicopathologic and molecular features of immunotherapeutic patients in MSKCC and GLCI cohorts.
Supplementary Table 2 from Genome-Wide Study of Hypomethylated and Induced Genes in Patients with Liver Cancer Unravels Novel Anticancer Targets

Barbara Stefańska,David Cheishvili,Matthew Suderman,Ani Arakelian,Jikun Huang,Michael Hallett,Ze‐Guang Han,Mamun Al‐Mahtab,Sheikh Mohammad Fazle Akbar,Wasif Ali Khan,Rubhana Raqib,Imrana Tanvir,Haseeb Ahmed Khan,Shafaat A. Rabbani,Moshe Szyf

DOI: https://doi.org/10.1158/1078-0432.22452293.v1

2023-01-01

Abstract:PDF file - 71KB, Supplementary Table S2. A list of kinases whose phosphorylation was examined in SkHep1 liver cancer cells after RASAL2, NENF or combined RASAL2 and NENF depletion. The level of phosphorylation is expressed as a percentage of phosphorylation in the control - cells transfected with scrambled siRNA. Phosphorylation of a panel of 26 kinases was assessed using Proteome Profiler Array (R&D Systems Inc., MN, USA).

Supplementary Table S2 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Supplementary Table S4 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Supplementary Table S1 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

SUPPLEMENTARY DATA FIGURES from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Data from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Supplementary Tables from LIMS1 Promotes Pancreatic Cancer Cell Survival under Oxygen–Glucose Deprivation Conditions by Enhancing HIF1A Protein Translation

Receptor-interacting protein kinase 2 is an immunotherapy target in pancreatic cancer

Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 2 from HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma

Supplementary Table S2 from an Inflammatory Checkpoint Generated by IL1RN Splicing Offers Therapeutic Opportunity for KRAS-Mutant Intrahepatic Cholangiocarcinoma

Supplementary Table S1 from an Inflammatory Checkpoint Generated by &lt;i&gt;il1rn&lt;/i&gt; Splicing Offers Therapeutic Opportunity for &Lt;i&gt;kras&lt;/i&gt;-Mutant Intrahepatic Cholangiocarcinoma

Supplementary Table S3 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy

Supplementary Table 2 from MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

Supplementary Table S5 from an Inflammatory Checkpoint Generated by IL1RN Splicing Offers Therapeutic Opportunity for KRAS-Mutant Intrahepatic Cholangiocarcinoma

Supplementary Tables from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy

Additional File 29 of Proteogenomic Insights into the Biology and Treatment of Pancreatic Ductal Adenocarcinoma

Supplementary Table S3 from Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non–Small Cell Lung Cancer

Supplementary Table 2 from Activation of the PI3K/AKT Pathway Induces Urothelial Carcinoma of the Renal Pelvis: Identification in Human Tumors and Confirmation in Animal Models

Supplementary Table I and II from PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer

Supplementary Table S2 from Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Supplementary Table 2 from Genome-Wide Study of Hypomethylated and Induced Genes in Patients with Liver Cancer Unravels Novel Anticancer Targets

Supplementary Table S1 from an Inflammatory Checkpoint Generated by <i>il1rn</i> Splicing Offers Therapeutic Opportunity for &Lt;i>kras</i>-Mutant Intrahepatic Cholangiocarcinoma